Generic Cancer Medicines in India: Options, Safety & Cost Savings

Introduction

Managing cancer can be expensive, especially when it involves long-term therapy, multiple medicines, or newer targeted and biologic treatments^1,2. This can cause a significant cost burden in the lives of patients and their families. 

To help ease this burden, generic cancer medicines can offer a more affordable option (when a suitable generic is available)³. It can help reduce costs without compromising the medicine’s therapeutic effect. 

This blog explains generic medicines for cancer, how they compare with branded medicines, their safety and effectiveness, potential cost savings, and what patients should consider before switching or choosing one. 

What Are Generic Cancer Medicines?

Generic cancer medicines are medicines that contain the same active ingredient as any branded cancer medicine^3,4. They are usually available at a lower cost because the manufacturer does not have to spend money on early drug development and marketing of the product⁵. This does not mean that they are not effective. Just like any branded medicine, generics are also approved only after they meet required quality, safety, and effectiveness standards^4,5,6. 

Note: Many branded medicines for cancer may not have conventional generic versions. Instead, biosimilars may be available. Biosimilars are closely similar versions of the original biological medicine (medicines derived from living organisms)⁷. They also undergo specific regulatory evaluation to demonstrate comparable quality, safety, and effectiveness to the reference biological medicine⁸. 

Benefits and Limitations of Generic Cancer Medicines

Generic medicines for cancer can make treatment more affordable, but they may also have some limitations. Both are discussed below: 

Benefits 

• Generics are often less expensive than their branded equivalents. This could help reduce overall treatment expenses³.
• An approved generic contains the same active ingredient as the corresponding branded medicine, so they work just similar to their branded counterparts⁴.
• Generic medicines meet regulatory requirements for quality, safety, and effectiveness before approval⁶.

Limitations

• Some newer or patented cancer medicines may not yet have generic versions^6,9.
• Some generic cancer medicines may not be readily available in every pharmacy or location⁹.
• A doctor may need to consider the specific medicine, dose, formulation, and treatment plan before switching. Not all medicines can be switched freely. 

Are Generic Medicines Available for Cancer Treatment in India?

Generic medicines are available for cancer treatment in India, including several commonly used chemotherapy medicines. The Government of India’s Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) provides affordable generic medicines through Jan Aushadhi Kendras, including several anticancer medicines. A 2021 study³ comparing anticancer medicines available through Jan Aushadhi pharmacies with their branded counterparts found that generic versions were available for several commonly used cancer medicines. It was also observed that most of the generics studied were substantially less expensive than their branded alternatives³.

However, availability depends on the specific cancer medicine, strength, formulation, and location. Not every cancer medicine has a generic equivalent, particularly newer medicines that may still be under patent protection. In addition, even when a generic medicine exists, it may not always be available at every pharmacy. A study of essential anticancer medicines in New Delhi also found that availability varied considerably between public hospitals, private hospitals, and retail pharmacies⁹.

Important: Patients should not switch from a prescribed branded cancer medicine to a generic medicine for cancer on their own. Your oncologist should confirm that the generic contains the appropriate active ingredient, strength, dosage form, and is suitable for your treatment plan. 

Which Cancer Medicines Are Available as Generics?

A 2021 study³ identified several anticancer medicines available as Jan Aushadhi generics, including: 

• Paclitaxel: Used for cancers such as breast, ovarian, and other cancers. 
• Docetaxel: Commonly used for breast cancer. 
• Doxorubicin: Used for several cancers, including breast cancer and lymphomas. 
• Carboplatin: Used for oesophageal, ovarian, breast, and other cancers. 
• Cisplatin: Used for head and neck, cervical, oesophageal, gastric cancers, and other cancers. 
• Gemcitabine: Used for ovarian, fallopian, and other cancers. 
• Oxaliplatin: Mainly used for colorectal cancers. 
• Capecitabine: Used for breast, gastric, and other cancers. 
• 5-Fluorouracil (5-FU): Used for gastric and other cancers. 
• Cyclophosphamide: Used for breast cancer, lymphomas, and other cancers^3,10.
• Etoposide: Used for lung cancer and several blood cancers^3,11. 
• Methotrexate: Used for certain blood cancers and other cancers^3,12.

How Are Generic Cancer Medicines Approved and Regulated in India?

Generic medicines for cancer must meet India’s regulatory requirements as per the Central Drugs Standard Control Organisation (CDSCO). The process generally involves^13,14:

• Application: The manufacturer submits details about the medicine, manufacturing process, quality, and stability to the regulatory authorities. 
• Quality testing: The medicine is tested to ensure it meets required standards for strength, purity, quality, and safety in terms of Good Manufacturing Practices (GMPs) 
• Bioequivalence: Where required, studies are conducted to show that the generic works in the body in a similar way to the reference medicine. 
• Regulatory review: CDSCO and the relevant state authorities review the submitted information before approval. 
• Post-approval monitoring: Once approved, the medicine continues to be monitored for quality and safety. 

Also Read: Generic Medicines for High Blood Pressure: Safety, Types & Benefits 

Where Can Generic Cancer Medicines Create the Biggest Savings?

Generic medicines for cancer can help reduce the financial burden of treatment, particularly when medicines are expensive or need to be taken repeatedly over several treatment cycles. Here is how and where you could save: 

• Chemotherapy medicines: Generics of commonly used medicines such as paclitaxel, docetaxel, gemcitabine, and oxaliplatin can be considerably cheaper than their branded counterparts^3,15 
• Repeated treatment: Savings on each dose can add up when treatment requires multiple cycles. This helps to reduce the overall medicine cost¹⁵.
• Reduced out-of-pocket expenses: Lower medicine costs can help make cancer treatment more affordable and reduce the financial burden on patients and families^3,16.

Note: The actual savings could vary by medicine, dose, manufacturer, pharmacy, treatment regimen, and availability.  

Should You Switch From a Branded Cancer Medicine to a Generic?

A generic should only be substituted when the treating oncologist confirms that the alternative is appropriate. Follow these simple steps to make the switch safely: 

• Talk to your oncologist: Ask whether an approved generic version is suitable for your specific treatment. 
• Check the medicine: Confirm that the generic has the same active ingredient, strength, dosage form, and route of administration as the prescribed medicine. 
• Get a prescription: Do not independently replace a prescribed cancer medicine. In India, substitution should be done with the prescribing doctor’s consent¹⁷.
• Use a reliable pharmacy: You can ask about availability at a Jan Aushadhi Kendra or other licensed pharmacy. 
• Continue the prescribed schedule: Once the switch is approved, take the generic at the same prescribed dose and schedule unless your oncologist advises otherwise. 
• Monitor your treatment: Continue regular appointments and inform your oncologist about any new or unusual side effects. 

Conclusion

Generic cancer medicines can make cancer treatment more affordable and may significantly reduce patients’ out-of-pocket expenses. Many commonly used cancer medicines are available as generics in India, while some biological cancer medicines have biosimilar alternatives.  

However, lower cost should not be the only consideration. Patients should use medicines that meet regulatory quality standards and consult their oncologist before switching from a branded medicine to a generic or biosimilar.  

Frequently Asked Questions (FAQs)

References

1. Muralidharan S, Gore M, Katkuri S. Cancer care and economic burden—A narrative review. J Fam Med Prim Care. 2023;12(12):3042-3047. doi:10.4103/jfmpc.jfmpc_1037_23. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10866236/

2. Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. Am Soc Clin Oncol Educ Book. 2021;(41):e1-e12. doi:10.1200/EDBK_100028. Available from: https://www.researchgate.net/publication/351384786_An_Arm_and_a_Leg_The_Rising_Cost_of_Cancer_Drugs_and_Impact_on_Access 

3. George T, Baliga MS. Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study. Cureus. 13(11):e19231. doi:10.7759/cureus.1923. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8642137/ 

4. Joshi S, Shetty Y, Karande S. Generic drugs – The Indian scenario. J Postgrad Med. 2019;65(2):67-69. doi:10.4103/jpgm.JPGM_420_18. Available from: https://pubmed.ncbi.nlm.nih.gov/31036775/

5. Behera DK, Rahut DB, Mehboobali MD, Tasneem SH, Rajendhran A. Medicine affordability and access in India: lessons from generic–branded price variation under the Jan Aushadhi Scheme. Front Public Health. 13:1629835. doi:10.3389/fpubh.2025.1629835. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12715599/

6. Generic Drug Facts. FDA. Published online June 2, 2026. Accessed September 16, 2026. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts 

7. Malakar S, Gontor EN, Dugbaye MY, et al. Cancer treatment with biosimilar drugs: A review. Cancer Innov. 2024;3(2):e115. doi:10.1002/cai2.115. Available from: https://www.researchgate.net/publication/379683606_Cancer_treatment_with_biosimilar_drugs_A_review

8. Cordeiro MA, Vitorino C, Sinogas C, Sousa JJ. A Regulatory Perspective on Biosimilar Medicines. Pharmaceutics. 2024;16(3):321. doi:10.3390/pharmaceutics16030321. Available from: https://www.researchgate.net/publication/378502770_A_Regulatory_Perspective_on_Biosimilar_Medicines

9. Faruqui N, Martiniuk A, Sharma A, et al. Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India. BMJ Glob Health. 2019;4(2):e001379. doi:10.1136/bmjgh-2018-001379. Available from: https://pubmed.ncbi.nlm.nih.gov/31139456/

10. List of new drug approvals Jan 2020 – June 2026. CDSCO. Accessed September 16, 2026. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadBiologicalrDNA/CT-21%20Approvals%20Jan%202020%20-%20June%202026.pdf 

11. Reyhanoglu G, Tadi P. Etoposide. StatPearls Publishing; 2026. Accessed September 16, 2026. http://www.ncbi.nlm.nih.gov/books/NBK557864/ 

12. Methotrexate Sodium (Cancer Treatment). NCI. May 21, 2008. Accessed September 16, 2026. https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate-sodium 

13. A comparative study of regulatory requirements for filing generic drug product between USA, India, and China. Accessed September 16, 2026. https://www.researchgate.net/publication/344758667_A_COMPARATIVE_STUDY_OF_REGULATORY_REQUIREMENTS_FOR_FILING_GENERIC_DRUG_PRODUCT_BETWEEN_USA_INDIA_AND_CHINA 

14. Draft Guidance  On Approval Of Clinical Trials  & New Drugs. CDSCO. Accessed September 16, 2026. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/New-Drugs/Guidelines/Guidance_for_New_Drug_Approval-23july2.pdf 

15. Lopes G de L. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol Off J Eur Soc Med Oncol. 2013;24 Suppl 5:v13-16. doi:10.1093/annonc/mdt323. Available from: https://pubmed.ncbi.nlm.nih.gov/23975699/

16. Krishna A, Simon P, Palatty PL, et al. Cost analysis of anticancer chemotherapy and chemoirradiation regimens considering the drugs marketed through Jan Aushadhi (People’s Medicine) stores and their branded counterparts: First cost comparison study. J Cancer Res Ther. 2024;20(5):1472-1485. doi:10.4103/jcrt.jcrt_2387_22. Available from: https://pubmed.ncbi.nlm.nih.gov/39412911/

17. Kairi JK, Sharma AK. Substitutes of Prescription Medicines – A Review of Concerns Relevant to Doctors and Patients. J Clin Diagn Res JCDR. 2017;11(8):FE01-FE05. doi:10.7860/JCDR/2017/28552.10439. Available from: https://www.jcdr.net/articles/PDF/10439/28552_CE[Ra]F(Sh)PF1(SY_MJ_PY)_PFA(SY_SS).pdf

18. Biosimilars: expanding access to essential biologic therapies. WHO. Accessed September 16, 2026. https://www.who.int/news/item/13-02-2025-biosimilars–expanding-access-to-essential-biologic-therapies 

19. Pradhan Mantri Bhartiya Janaushadhi Kendras. Accessed September 16, 2026. Avaiable from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2297568&reg=48&lang=1

20. Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomed Pharmacother. 2020;125:110009. doi:10.1016/j.biopha.2020.110009. Available from: https://pubmed.ncbi.nlm.nih.gov/32106381/

Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof. 

Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.